ArticleFrontiers in immunology2022
Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Sudden unexpected death in epilepsy and ictal asystole in patients with autoimmune encephalitis: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Efficacy of immunotherapy and prognosis in anti-LGI1 encephalitis patients: A meta-analysis.Annals of clinical and translational neurology · 2023Pooled it
- Suspected encephalitis in adults.Practical neurology · 2026Review
- Article
- Combination Versus Monotherapy in Acute Anti-LGI1 Encephalitis: A Real-World Dose Optimization Analysis.Neuropsychopharmacology reports · 2026Article
- Nationwide Analysis of In-Hospital Mortality in Patients with Encephalitis-Related Diagnoses in Ecuador.Diseases (Basel, Switzerland) · 2026Article
- Clinical Features, Antibody Profiles, and Prognostic Factors in Autoimmune Encephalitis: A Single-Center Study.Journal of clinical medicine · 2025Article
- Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis: A Multicenter Cohort Study.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae.Journal of neurology, neurosurgery, and psychiatry · 2025Observational
- Synapse vulnerability and resilience across the clinical spectrum of dementias.Nature reviews. Neurology · 2025Review
- Efficacy of rituximab as second-line therapy for autoimmune encephalitis: A systematic review and meta-analysis.Heliyon · 2025Article
- Autoimmune encephalitis in Latin America. Clinical features and outcomes in pediatric and adult populations: retrospective cohort of The REAL LABIC Project.Frontiers in neurology · 2025Article
- Article
- Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABANeurology(R) neuroimmunology & neuroinflammation · 2024Article
- Assessment of disease severity and patient prognosis in anti-GABAFrontiers in neurology · 2023Article
- Long-term efficacy and safety of different corticosteroid courses plus mycophenolate mofetil for autoimmune encephalitis with neuronal surface antibodies without tumor.Frontiers in immunology · 2023Article
- Diffusion kurtosis imaging and diffusion tensor imaging parameters applied to white matter and gray matter of patients with anti-N-methyl-D-aspartate receptor encephalitis.Frontiers in neuroscience · 2022Article
- Case Report: Paroxysmal hyperhidrosis as an initial symptom in a patient with anti-LGI1 encephalitis.Frontiers in immunology · 2022Article
- Relapses of Anti-NMDAR, Anti-GABABR and Anti-LGI1 Encephalitis: A Retrospective Cohort Study.Frontiers in immunology · 2022Article
- A fatal case of Anti-NMDAR encephalitis with fulminant psychosis.Industrial psychiatry journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to investigate the mortality rate and identify the predictors of death in patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis. Methods: Patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis were recruited from the Neurology Department of the First Hospital of Jilin University from March 2015 to November 2021. The primary outcome variable was a binary variable of death vs. survival. The potential risk factors for mortality were evaluated. The mortality rates were determined, and the independent predictors of death were identified using multivariable logistic regression analysis. Results: A total of 100 hospitalized patients with anti-NMDAR, anti-LGI1, or anti-GABABR encephalitis were included in the final analysis. Fifteen patients (15%) died during a median follow-up period of 18 months. The mortality rates were 10% for anti-NMDAR encephalitis, 2.8% for anti-LGI1 encephalitis, and 41.7% for anti-GABABR encephalitis. The multivariable analysis results showed that older age at onset [adjusted odds ratio (OR) = 1.017, 95% confidence interval (CI) = 1.009-1.136; Conclusion: The general mortality rate of anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis was 15%. Age at onset and type of autoimmune encephalitis antibody were independent predictors of death in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.